Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
Biagio RicciutiGonzalo RecondoLiam F SpurrYvonne Y LiGiuseppe LambertiDeepti VenkatramanRenato UmetonAndrew D CherniackMizuki NishinoLynette M ShollGeoffrey I ShapiroMark M AwadMichael L ChengPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Deleterious DDR mutations are frequent in NSCLC and are associated with improved clinical outcomes in patients with NSCLC treated with PD-(L)1 blockade.